T. Rowe Price holds 2.7% of Hologic stock
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Hologic, Inc. common stock as of December 31, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Hologic, Inc. common stock as of December 31, 2025.
The firm reports beneficial ownership of 5,932,301 shares of Hologic common stock, representing 2.7% of the class. It has sole power to vote 5,914,773 shares and sole power to dispose of 5,932,301 shares, with no shared voting or dispositive power.
The filer states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hologic. It also expressly denies that this filing should be construed as an admission of beneficial ownership of the reported securities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Hologic (HOLX) does T. Rowe Price report in this Schedule 13G/A?
What dispositive power does T. Rowe Price report for its Hologic (HOLX) position?
Is T. Rowe Price’s Hologic (HOLX) holding intended to influence control of the company?
Why does the Schedule 13G/A for Hologic (HOLX) mention ownership of 5 percent or less?
AI-generated analysis. How Rhea-AI works. Not financial advice.